 |
 |
| January 27, 2012 |
Proteonomix, Inc. |
 |
PROTEONOMIX, INC.'s (PROT) CEO to Present at Investor Summit 2012 Sponsored by Merriman Capital in New York on February 1, 2012. |
 |
MOUNTAINSIDE, NJ--(Marketwire -01/27/12)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it will be presenting at the Investor Summit 2012 on February 1, 2012, sponsored by Merriman Capital at the Intercontinental Time Square Hotel in New York City. |
|
| Read Full Story > |
|
 |
| January 4, 2012 |
Proteonomix, Inc. |
|
Proteonomix, Inc. (PROT) Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients With End Stage Liver Disease. |
|
MOUNTAINSIDE, NJ--(Marketwire -01/04/12)- Proteonomix, Inc. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Company's clinical trial of UMK-121 has received IRB (Institutional Review Board) approval and is now ready for the recruitment of patients. |
|
| Read Full Story > |
|
 |
| December 27, 2011 |
Proteonomix, Inc. |
|
Proteonomix, Inc. (PROT) Announces Completion of Payment for Its Clinical Trial of UMK-121 in Patients With End Stage Liver Disease. |
|
MOUNTAINSIDE, NJ--(Marketwire -12/27/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has completed all payments required from Proteonomix to commence a Clinical Study entitled "UMK-121 in Patients with Liver Disease." |
|
| Read Full Story > |
|
 |
| December 7, 2011 |
Proteonomix, Inc. |
|
Proteonomix, Inc. (PROT) Letter to Shareholders. |
|
Dear Shareholders: This has been a momentous year for your Company. During the past several years we have asserted that our business lines would move forward in both the cosmetic area via our Proteoderm subsidiary and in the biopharmaceutical lines, most recently our UMK-121 technology. |
|
| Read Full Story > |
|
 |
| November 21, 2011 |
Proteonomix, Inc. |
|
Proteonomix, Inc. (PROT) Announces Material Agreement With the University of Miami to Conduct a Clinical Study of UMK 121 in Patients With End Stage Liver Disease. |
|
MOUNTAINSIDE, NJ--(Marketwire -11/21/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has entered into an agreement with the University of Miami ("The University") to conduct a Clinical Study entitled "UMK 121 in Patients with Liver Disease." |
|
| Read Full Story > |
|
<< Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Next >> |
|
